Open Access Repository
Vaccination strategies for Alzheimer's disease: a new hope?
Downloads
Downloads per month over past year

![]() |
PDF
3996.pdf | Request a copy Full text restricted Available under University of Tasmania Standard License. |
Abstract
The pathological hallmarks of Alzheimer’s disease (AD) include β-amyloid (Aβ) plaques, dystrophic neurites and neurofibrillary pathology, which eventually result in the degeneration of neurons and subsequent dementia. In 1999, international interest in a new therapeutic approach to the treatment of AD was ignited following transgenic mouse studies that indicated that it might be possible to immunise against the pathological alterations in Aβ that lead to aggregation of this protein in the brain. A subsequent phase I human trial for safety, tolerability and immunogenicity using an active immunisation strategy against Aβ had a positive outcome. However, phase IIA human trials involving active immunisation were halted following the diagnosis of aseptic meningoencephalitis in 6% of immunised subjects. Research into immunisation strategies involving transgenic AD mouse models has subsequently been refocused to determine the mechanisms by which plaque clearance and reduced memory deficits are attained, and to establish safer therapeutic approaches that may reduce potentially harmful brain inflammation. The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition.
Item Type: | Article |
---|---|
Authors/Creators: | Woodhouse, A and Dickson, TC and Vickers, JC |
Journal or Publication Title: | Drugs and Aging |
Publisher: | Adis International Ltd. |
ISSN: | 1170-229X |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |